Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.275 USD -4.28% Market Closed
Market Cap: 72.6m USD

Intrinsic Value

ADAP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ADAP stock under the Base Case scenario is 1.395 USD. Compared to the current market price of 0.275 USD, Adaptimmune Therapeutics PLC is Undervalued by 80%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADAP Intrinsic Value
1.395 USD
Undervaluation 80%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Adaptimmune Therapeutics PLC

Valuation History Unavailable

Historical valuation for ADAP cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Adaptimmune Therapeutics PLC
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Adaptimmune Therapeutics PLC

Current Assets 103m
Cash & Short-Term Investments 59.6m
Receivables 20.9m
Other Current Assets 22.6m
Non-Current Assets 55.1m
PP&E 48.9m
Intangibles 3.8m
Other Non-Current Assets 2.3m
Efficiency

Free Cash Flow Analysis
Adaptimmune Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Adaptimmune Therapeutics PLC

Revenue
179.6m USD
Cost of Revenue
-170.1m USD
Gross Profit
9.6m USD
Operating Expenses
-56.6m USD
Operating Income
-47m USD
Other Expenses
-22.9m USD
Net Income
-69.9m USD
Fundamental Scores

ADAP Profitability Score
Profitability Due Diligence

Adaptimmune Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional 1-Year Revenue Growth
ROE is Increasing
35/100
Profitability
Score

Adaptimmune Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

ADAP Solvency Score
Solvency Due Diligence

Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
51/100
Solvency
Score

Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

Wall Street analysts forecast ADAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADAP is 1.74 USD with a low forecast of 1.01 USD and a high forecast of 3.15 USD.

Lowest
Price Target
1.01 USD
267% Upside
Average
Price Target
1.74 USD
533% Upside
Highest
Price Target
3.15 USD
1 045% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Adaptimmune Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for ADAP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ADAP Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ADAP stock?

The intrinsic value of one ADAP stock under the Base Case scenario is 1.395 USD.

Is ADAP stock undervalued or overvalued?

Compared to the current market price of 0.275 USD, Adaptimmune Therapeutics PLC is Undervalued by 80%.

Back to Top